Amivantamab has also shown promising results in metastatic NSCLC patients with common activating EGFR mutations, including use in the first-line setting in combination with lazertinib (a 3rd generation EGFR TKI) as studied in the MARIPOSA trial [66], as well as use in later lines in combination with chemotherapy +/− lazertinib (MARIPOSA-2) following disease progression on osimertinib [67]. Here, EGFR is linked to non-small cell lung carcinoma.